Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Methylphenidate Hydrochloride (CAS 298-59-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel ...

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above Monday, ...

Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and ...

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...

The Food and Drug Administration (FDA) has expressed concerns about the therapeutic equivalence of two generic versions of Concerta (methylphenidate HCl extended-release; Janssen) tablets indicated ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg ...

Medication offers relief from 'home to homework' 25 FEBRUARY 2002 – London, UK -- A new, once-daily treatment for attention deficit hyperactivity disorder (ADHD), Concerta® XL (methylphenidate HCl), ...

Methylphenidate HCl 10mg, 20mg, 30mg, 40mg; ext-rel caps (one-half as immediate-release + one-half as enteric-coated, delayed-release beads). Not recommended in pediatric patients <6yrs due to a ...

To compare efficacy of cognitive behavioral group psychotherapy with individual clinical management and methylphenidate hydrochloride with placebo, researchers conducted a prospective, multicenter ...